Leaflet GLICLAZIDA MEDREG 60mg prolonged-release tablets

Product code:
W69186001
Quantity:
10
Indicated for:
type 2 diabetes mellitus
Route of administration:
oral
Substance:
gliclazide (sulfonylurea antidiabetic)
ATC
A10BB09 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sulfonylureas

Precautions:

Hypoglycemia

Hypoglycemia

This medicine may lower blood sugar.

Gliclazide is an antidiabetic medication from the sulfonylurea class, used to control blood sugar levels in patients with type 2 diabetes. It works by stimulating the pancreas to produce more insulin, thereby helping to lower blood sugar levels.

It is recommended as part of a treatment plan that includes a balanced diet, regular physical activity, and blood sugar monitoring. Gliclazide is effective in preventing diabetes-related complications, such as damage to small blood vessels (retinopathy, nephropathy).

Side effects may include hypoglycemia (excessive drop in blood sugar), nausea, dizziness, or weight gain. It is important for patients to follow the prescribed dosage and watch for signs of hypoglycemia, such as shaking, sweating, or confusion.

General data about GLICLAZIDA MEDREG 60mg

Substance:
gliclazide
Date of latest medicines list:
01-11-2022
Product code:
W69186001
Concentration:
60mg
Pharmaceutical form:
prolonged-release tablets
Quantity:
10
Product type:
Generic medicine
Prescription status:
P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

Manufacturer:
MEDIS INTERNATIONAL A.S. - REPUBLICA CEHA
Holder:
MEDREG S.R.O. - REPUBLICA CEHA
Number:
14685/2022/01
Shelf life:
2 years

Pharmaceutical forms available for gliclazide

Concentrations available for gliclazide

  • 30mg
  • 60mg
  • 80mg
  • 90mg